Aligos Therapeutics, Inc. (ALGS) Stock Score, Valuation & Financial Research
Aligos Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 27/100.
Quick answer for ALGS
Aligos Therapeutics, Inc. currently has a Wall Street Score of 27/100. The stored market price is $5.22. Its financial score is 8/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Aligos Therapeutics, Inc. does
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a
ALGS financial snapshot
- Wall Street Score:
- 27/100
- Current price:
- $5.22
- Market capitalization:
- $32.3M
- Revenue:
- $31.5M
- Net income:
- $-76.0M
- Free cash flow:
- $-82.9M
- Cash:
- $30.4M
- Total debt:
- $3.5M
- EPS:
- -7.30
- Financial score:
- 8/100
- Valuation score:
- 0/100
- Revenue score:
- 29/100
What stands out
- Reported year-over-year revenue growth is +13.4%.
- Free cash flow is $-82.9M, showing cash burn in the current stored period.
- The balance sheet shows $30.4M of cash versus $3.5M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 8/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ALGS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.